Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Mechanistic aspects of maltotriose-conjugate translocation to the Gram-negative bacteria cytoplasm.

Dumont E, Vergalli J, Pajovic J, Bhamidimarri SP, Morante K, Wang J, Lubriks D, Suna E, Stavenger RA, Winterhalter M, Réfrégiers M, Pagès JM.

Life Sci Alliance. 2018 Dec 28;2(1):e201800242. doi: 10.26508/lsa.201800242. eCollection 2019 Feb.

2.

Getting Drugs into Gram-Negative Bacteria: Rational Rules for Permeation through General Porins.

Acosta-Gutiérrez S, Ferrara L, Pathania M, Masi M, Wang J, Bodrenko I, Zahn M, Winterhalter M, Stavenger RA, Pagès JM, Naismith JH, van den Berg B, Page MGP, Ceccarelli M.

ACS Infect Dis. 2018 Oct 12;4(10):1487-1498. doi: 10.1021/acsinfecdis.8b00108. Epub 2018 Aug 17.

PMID:
29962203
3.

Imidazopyrazinones (IPYs): Non-Quinolone Bacterial Topoisomerase Inhibitors Showing Partial Cross-Resistance with Quinolones.

Jeannot F, Taillier T, Despeyroux P, Renard S, Rey A, Mourez M, Poeverlein C, Khichane I, Perrin MA, Versluys S, Stavenger RA, Huang J, Germe T, Maxwell A, Cao S, Huseby DL, Hughes D, Bacqué E.

J Med Chem. 2018 Apr 26;61(8):3565-3581. doi: 10.1021/acs.jmedchem.7b01892. Epub 2018 Apr 10.

PMID:
29596745
4.

A new class of antibacterials, the imidazopyrazinones, reveal structural transitions involved in DNA gyrase poisoning and mechanisms of resistance.

Germe T, Vörös J, Jeannot F, Taillier T, Stavenger RA, Bacqué E, Maxwell A, Bax BD.

Nucleic Acids Res. 2018 May 4;46(8):4325. doi: 10.1093/nar/gky241. No abstract available.

5.

A new class of antibacterials, the imidazopyrazinones, reveal structural transitions involved in DNA gyrase poisoning and mechanisms of resistance.

Germe T, Vörös J, Jeannot F, Taillier T, Stavenger RA, Bacqué E, Maxwell A, Bax BD.

Nucleic Acids Res. 2018 May 4;46(8):4114-4128. doi: 10.1093/nar/gky181.

6.

Thiophene antibacterials that allosterically stabilize DNA-cleavage complexes with DNA gyrase.

Chan PF, Germe T, Bax BD, Huang J, Thalji RK, Bacqué E, Checchia A, Chen D, Cui H, Ding X, Ingraham K, McCloskey L, Raha K, Srikannathasan V, Maxwell A, Stavenger RA.

Proc Natl Acad Sci U S A. 2017 May 30;114(22):E4492-E4500. doi: 10.1073/pnas.1700721114. Epub 2017 May 15.

7.

Discovery and Characterization of a Class of Pyrazole Inhibitors of Bacterial Undecaprenyl Pyrophosphate Synthase.

Concha N, Huang J, Bai X, Benowitz A, Brady P, Grady LC, Kryn LH, Holmes D, Ingraham K, Jin Q, Pothier Kaushansky L, McCloskey L, Messer JA, O'Keefe H, Patel A, Satz AL, Sinnamon RH, Schneck J, Skinner SR, Summerfield J, Taylor A, Taylor JD, Evindar G, Stavenger RA.

J Med Chem. 2016 Aug 11;59(15):7299-304. doi: 10.1021/acs.jmedchem.6b00746. Epub 2016 Jul 20.

PMID:
27379833
8.

Microspectrometric insights on the uptake of antibiotics at the single bacterial cell level.

Cinquin B, Maigre L, Pinet E, Chevalier J, Stavenger RA, Mills S, Réfrégiers M, Pagès JM.

Sci Rep. 2015 Dec 11;5:17968. doi: 10.1038/srep17968.

9.

Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin.

Chan PF, Srikannathasan V, Huang J, Cui H, Fosberry AP, Gu M, Hann MM, Hibbs M, Homes P, Ingraham K, Pizzollo J, Shen C, Shillings AJ, Spitzfaden CE, Tanner R, Theobald AJ, Stavenger RA, Bax BD, Gwynn MN.

Nat Commun. 2015 Dec 7;6:10048. doi: 10.1038/ncomms10048.

10.

The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance.

Kostyanev T, Bonten MJ, O'Brien S, Steel H, Ross S, François B, Tacconelli E, Winterhalter M, Stavenger RA, Karlén A, Harbarth S, Hackett J, Jafri HS, Vuong C, MacGowan A, Witschi A, Angyalosi G, Elborn JS, deWinter R, Goossens H.

J Antimicrob Chemother. 2016 Feb;71(2):290-5. doi: 10.1093/jac/dkv339. Epub 2015 Nov 15. Review.

PMID:
26568581
11.

TRANSLOCATION project: how to get good drugs into bad bugs.

Stavenger RA, Winterhalter M.

Sci Transl Med. 2014 Mar 19;6(228):228ed7. doi: 10.1126/scitranslmed.3008605. No abstract available.

12.

Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors.

Goodman KB, Cui H, Dowdell SE, Gaitanopoulos DE, Ivy RL, Sehon CA, Stavenger RA, Wang GZ, Viet AQ, Xu W, Ye G, Semus SF, Evans C, Fries HE, Jolivette LJ, Kirkpatrick RB, Dul E, Khandekar SS, Yi T, Jung DK, Wright LL, Smith GK, Behm DJ, Bentley R, Doe CP, Hu E, Lee D.

J Med Chem. 2007 Jan 11;50(1):6-9.

PMID:
17201405
13.

Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity.

Stavenger RA, Cui H, Dowdell SE, Franz RG, Gaitanopoulos DE, Goodman KB, Hilfiker MA, Ivy RL, Leber JD, Marino JP Jr, Oh HJ, Viet AQ, Xu W, Ye G, Zhang D, Zhao Y, Jolivette LJ, Head MS, Semus SF, Elkins PA, Kirkpatrick RB, Dul E, Khandekar SS, Yi T, Jung DK, Wright LL, Smith GK, Behm DJ, Doe CP, Bentley R, Chen ZX, Hu E, Lee D.

J Med Chem. 2007 Jan 11;50(1):2-5.

PMID:
17201404
14.

Chiral phosphoramide-catalyzed aldol additions of ketone trichlorosilyl enolates. Mechanistic aspects.

Denmark SE, Pham SM, Stavenger RA, Su X, Wong KT, Nishigaichi Y.

J Org Chem. 2006 May 12;71(10):3904-22.

PMID:
16674067
15.

A one-bead, one-stock solution approach to chemical genetics: part 1.

Blackwell HE, Pérez L, Stavenger RA, Tallarico JA, Cope Eatough E, Foley MA, Schreiber SL.

Chem Biol. 2001 Dec;8(12):1167-82.

16.

Enantioselective Ring Opening of Epoxides with Silicon Tetrachloride in the Presence of a Chiral Lewis Base.

Denmark SE, Barsanti PA, Wong KT, Stavenger RA.

J Org Chem. 1998 Apr 17;63(8):2428-2429. No abstract available.

PMID:
11672098
18.

Asymmetric catalysis of aldol reactions with chiral lewis bases.

Denmark SE, Stavenger RA.

Acc Chem Res. 2000 Jun;33(6):432-40. Review.

PMID:
10891061
19.

Cyclopropanation with Diazomethane and Bis(oxazoline)palladium(II) Complexes.

Denmark SE, Stavenger RA, Faucher AM, Edwards JP.

J Org Chem. 1997 May 16;62(10):3375-3389.

PMID:
11671727

Supplemental Content

Loading ...
Support Center